20250219_Isofol_Year-end report 2024
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
GOTHENBURG, Sweden, February 19, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's year-end report for January - December 2024 is now available on the company's website, www.isofolmedical.com.
The information in the press release is intended for investors.
CEO’s comment
” At the end of 2024, we received positive feedback on our clinical phase Ib/II-study from the German regulatory authority, BfArM, and we are now finalizing discussions on the definitive approach ahead of initiating the trial at the world leading hospital Charité in Germany. It is also gratifying that our Japanese partner Solasia Pharma K.K. has made a strategic decision to actively participate in the second part of the study. The fact that, we in addition were able to confirm during the quarter that the commercial potential of our project is at blockbuster level strengthens our conviction, and it is with renewed energy we leave 2024 behind and enter the next phase of the company's development,” says CEO Petter Segelman Lindqvist.
Fourth quarter, October – December 2024
- Net revenue amounted to kSEK 0 (0)
- The result for the period amounted to kSEK 13,102 (-8,883)
- Earnings per share amounted to SEK -0,08 (-0.05)
- Cash and bank balance on December 31 amounted to kSEK 96,157 (138,148)
January – December 2024
- Net revenue amounted to kSEK 0 (721)
- The result for the period amounted to kSEK -43,488 (-37,071)
- Earnings per share amounted to SEK -0.27 (-0.23)
- The Board of Directors proposes that no dividend will be paid for the 2024 financial year
Significant events during the fourth quarter 2024
- On October 23, the company announced that a Late Breaking Abstract regarding the drug candidate arfolitixorin was to be presented as a poster at ENA 2024 in Spain. The poster describes dose-dependent cytotoxic effects and increased activity of arfolitixorin at higher doses in combination with 5-FU.
- On November 20, the company presented an operational update during the investor meeting that took place in Gothenburg, and which was also available digitally via link. The company presented the evidence platform that forms the basis for the upcoming clinical study, the intended study design for the phase Ib/II study, and an update on the commercial potential of arfolitixorin.
- On November 21, the company announced that the investigator-initiated Modelle study, which evaluated the effect of arfolitixorin at the tissue level, has been published in the scientific journal BJC Reports. The study showed dose-dependent TS inhibition with arfolitixorin.
- On December 18, it was announced that the company's Japanese partner Solasia Pharma K.K. has made a strategic decision to include Japanese patients in the Phase II part of the upcoming Phase Ib/II clinical study of arfolitixorin in patients with metastatic colorectal cancer.
Significant events after the event of the period
- On January 27, 2025, Isofol announced that a post-hoc per protocol analysis of the AGENT study, conducted by an external expert committee, has been published as an abstract at ASCO-GI in the USA. The study shows significantly better effect of arfolitixorin in important regions.
For additional significant events that occurred during the year, please advise previous quarterly reports.
For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, CEO
E-mail: petter.s.lindqvist@isofolmedical.com
Telephone: +46 (0)739 60 12 56
Margareta Hagman, CFO
E-mail: margareta.hagman@isofolmedial.com
Telephone: +46 (0)738 73 34 18
The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET, on February 19, 2025.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a research-based biotechnology company working to improve the prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is urgent. A phase Ib/II study is now being conducted with new dosing regimens that are expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.